All In Biotech

Drug Trial Radar · NCT06089278

A Clinical Study of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps.

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trials to Assess the Effectiveness, Safety and Pharmacokinetics of TQH2722 Injection in Patients With Chronic Sinusitis With or Without Nasal Polyps.

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

160

Actual

Start

Dec 28, 2023

Primary completion

Mar 30, 2025

Study completion Apr 30, 2025

Sponsor

Sponsor type
Industry
First posted
Oct 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the effectiveness, safety and pharmacokinetics of TQH2722 injection in patients with chronic sinusitis with or without nasal polyps.

Conditions

  • Sinusitis

Interventions

  • 300mg of TQH2722 injectionDrug

    TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.

  • 600mg of TQH2722 injectionDrug

    TQH2722 injection is a fully human monoclonal antibody that interfering with the signal cascade.

  • TQH2722 injection matching placeboDrug

    Placebo without active substance.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in the nasal polyp score of subjects with chronic rhinosinusitis with nasal polyps (CRSwNP) from baseline at week 16 in part ATime frame: Up to 16 weeks.
  2. Changes in the Lund-Mackay score of sinus CT scans of subjects with chronic rhinosinusitis without nasal polyps (CRSsNP) from baseline at week 16 in part BTime frame: Up to 16 weeks.

Locations

36 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Wannan Medical College

    Wuhu, Anhui, China

  • Beijing Hospital

    Beijing, Beijing Municipality, China

  • Beijing TongRen Hospital, Capital Medical University

    Beijing, Beijing Municipality, China

  • Lanzhou University Second Hospital

    Lanzhou, Gansu, China

  • Foshan First People's Hospital

    Foshan, Guangdong, China

  • Jieyang People's Hospital

    Jieyang, Guangdong, China

  • The Second People's Hospital of Shenzhen

    Shenzhen, Guangdong, China

  • The People's Hospital of Guangxi Zhuang Autonomous Region

    Nanning, Guangxi, China

  • The Affiliated hospital of Guizhou Medical University

    Guiyang, Guizhou, China

  • Cangzhou Central Hospital

    Cangzhou, Hebei, China

  • Hebei Medical University Third Hospital

    Shijiazhuang, Hebei, China

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, China

  • Union Hospitalc, Tongji Medical College, Huazhong, University of Science and Technology

    Wuhan, Hubei, China

  • Renmin Hospital of Wuhan University

    Wuhan, Hubei, China

  • Loudi Central Hospital

    Changsha, Hunan, China

  • Baotou Central Hospital

    Baotou, Inner Mongolia, China

  • The Affiliated Hospital of Inner Mongolia Medical University

    Hohhot, Inner Mongolia, China

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, China

  • The First Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China

  • Jilin Province People's Hospital

    Changchun, Jilin, China

  • The Affiliated Hospital of Yanbian University

    Yanji, Jilin, China

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China

  • Shengjing Hospital of China Medical University

    Shenyang, Liaoning, China

  • Central Hospital of Shenyang Medical College

    Shenyang, Liaoning, China

  • Shandong Second People's Hospital

    Jinan, Shandong, China

  • Weifang Second People's Hospital

    Weifang, Shandong, China

  • Weihai Central Hospital

    Weihai, Shandong, China

  • Yantai Yuhuangding Hospital

    Yantai, Shandong, China

  • Zibo Central Hospital

    Zibo, Shandong, China

  • Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine

    Shanghai, Shanghai Municipality, China

  • First Hospital of Shanxi Medical University

    Taiyuan, Shanxi, China

  • Chengdu Second People's Hospital

    Chengdu, Sichuan, China

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China

  • The First Affiliated Hospital of Xinjiang Medical University

    Ürümqi, Xinjiang, China

  • Wenling First People's Hospital

    Taizhou, Zhejiang, China

  • Taizhou central hospital

    Taizhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.